Argentina approves Sputnik Light as stand-alone vaccine and booster

The Russian Direct Investment Fund (RDIF, the sovereign wealth fund of the Russian Federation) announces & nbsp; approval of the use of the Russian single-component vaccine & ldquo; ; Satellite Light & rdquo; as an independent drug and & nbsp; in & nbsp; as a boosting injection & raquo;, & nbsp; & mdash; says the & nbsp; message.

Sputnik Light is the first component (recombinant human adenovirus 26 serotype (rAd26) of the Sputnik V vaccine.

Argentina was one of the & nbsp; first countries in the & nbsp; world to register Sputnik V in & nbsp; December 2020. The National Administration for & nbsp; Control of & nbsp; Medicines, Foods and & Nbsp; Medical Technologies (ANMAT) approved the vaccine based on & nbsp; Russian data without & nbsp; additional clinical trials in & nbsp; Argentina. 'Sputnik V' became one of the & nbsp; key vaccines that were used in the & nbsp; country during the & nbsp; vaccination campaign, which & nbsp; helped to reduce the incidence of coronavirus & nbsp; 35 times per & nbsp; for four months.

Study in & nbsp; Argentina to evaluate the combined use of Sputnik Light and & nbsp; vaccines from AstraZeneca, Sinopharm, Moderna and & nbsp; Cansino have demonstrated that & nbsp; & nbsp; & quot; Sputnik Light & raquo; & nbsp; & mdash; effective universal booster for these vaccines. Each combination (“ vaccine cocktail '') with & nbsp; application of Sputnik Light provided a higher titer of antibodies on the & nbsp; 14th day after the introduction of the second dose according to & nbsp; compared with & nbsp; homogeneous vaccination schemes with each of & nbsp; drugs (one and & nbsp; the & nbsp; same & nbsp; vaccine in & nbsp; quality and & nbsp; first, and & nbsp; second dose) RDIF.

The Fund indicates that the & nbsp; efficiency of Sputnik Light against the delta variant of coronavirus in & nbsp; as a boost injection for & nbsp; other vaccines will be close to & nbsp; efficiency indicators of Sputnik V & nbsp; & mdash; more than 83% against infection and & nbsp; more than 94% against hospitalization.

Data published in a number of countries confirm the high safety and & nbsp; effectiveness of Sputnik Light. in the course of vaccination of the population. In particular, data from the Ministry of Health of the province of Buenos Aires (Argentina) showed the effectiveness of Sputnik Light. at & nbsp; 78.6 & minus; 83.7% with & nbsp; vaccination of the elderly.